Non Invasive Prenatal Testing Market Revenues and Volume by Test and Forecast 2022

Non-invasive prenatal testing (NIPT), also referred to as non-invasive prenatal diagnosis, is a method of screening employed for detecting specific types of chromosomal abnormalities that may take place in a developing fetus. These chromosomal abnormalities are Turner syndrome (monosomy X), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Down syndrome (trisomy 21). This type of testing involves a blood test for assessing the fetal DNA within the maternal bloodstream. Along with diagnosing the probability of developing any chromosomal abnormalities in a fetus, this test is also utilized for determining the sex of the baby and rhesus (Rh) blood type. The conventionally utilized invasive prenatal genetic tests such as chorionic villus sampling (CVS) and amniocentesis involved the risk of miscarriage and hence are being substituted with NIPT.

Obtain the Sample Containing the Upcoming Market Analysis of Non Invasive Prenatal Testing at: http://bit.ly/2lpfYnd

According to the research report’s estimates, the global non-invasive prenatal testing market was worth US$0.5 bn in 2013 and is expected to grow at an incredible CAGR of 17.50% from 2014 to 2022 to reach a figure of US$2.4 bn by 2022. The impressive growth of the global non-invasive prenatal testing market is mainly due to the growing chances of fetuses developing chromosomal disorders such as Down syndrome, Turner syndrome, Edwards syndrome, Patau syndrome, and others. Non-invasive prenatal testing equipment is used for screening pregnant women who might have fetuses with these complications due to, among other reasons, higher maternal age than average.

The global non-invasive prenatal testing market is segmented on the basis of test and region. The tests in this market are Harmony, MaterniT21 PLUS, NIFTY, BambniTest, informaSeq, Panorama, VisibiliT, PrenaTest, verify, and others. Geographically, the global non-invasive prenatal testing market is segmented into Europe, Asia Pacific, North America, and Rest of the World.

All of these tests use the mother’s blood to study the cell-free fetal DNA. Back in 2011, MaterniT21 PLUS was the first ever non-invasive prenatal test launched in the market for diagnosing trisomy 21. Over the course of two years, this diagnostic test had already grabbed a share of 36.1% in the overall market. However, analysts predict that as the popularity of other testing equipment such as NIFTY, Panorama, and verify grows, MaterniT21 PLUS’ share will drop. Furthermore, demand for the Bambni test, which was recently approved by the CFDA, will also shoot upwards in the coming years.

Unfortunately, the global non-invasive prenatal testing market faces certain hurdles such as a tough regulatory framework and conservative ethical outlook towards prenatal testing. The other challenges complicating this situation are limitations of non-invasive prenatal tests and alternative screening and testing methods. However, the emerging economies of Asia Pacific are offering a new avenue for growth to the global non-invasive prenatal testing market in the near future.

Read Current Market Status of Non-Invasive Prenatal Testing at: http://www.transparencymarketresearch.com/noninvasive-prenatal-diagnostics-market.html

Some of the important companies profiled in the global non-invasive prenatal testing market report are Laboratory Corporation of America Holdings, Natera Inc., Illumina Inc., Berry Genomics Co. Ltd., LifeCodexx AG, BGI Diagnostics, Sequenom Inc., and Ariosa Diagnostics Inc. The research report gives a complete understanding of the competitive landscape of the market and offers an insight into the financial overview, product portfolio, research and development activities, business and marketing strategies, and investment outlook in the coming years.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/